LOC100039248 inhibitors encompass a specialized group of chemical compounds designed to target and inhibit the activity of the protein encoded by the gene LOC100039248. This gene is notable for its specific expression patterns and presumed role in cellular functions, although its full biological significance remains an area of active research. The protein produced by LOC100039248, like many such proteins encoded by genes of interest, is thought to be involved in critical regulatory processes within cells. The development of inhibitors against this protein requires a comprehensive understanding of its molecular structure, the pathways it influences, and the nature of its interactions within the cell. The primary aim in creating LOC100039248 inhibitors is to disrupt the functional interactions of this protein, thereby inhibiting its role in the cellular processes it affects. This involves identifying crucial domains or active sites within the protein that are essential for its function and designing molecules that can bind to these sites, impeding the protein's normal activity.
The process of developing LOC100039248 inhibitors is a multifaceted challenge that integrates expertise from the fields of biochemistry, molecular biology, and pharmacology. Researchers engaged in this endeavor concentrate on deciphering the detailed structural characteristics of the LOC100039248 protein. Advanced techniques are employed to map out the protein's structure, especially focusing on regions critical for its function. Understanding these structural aspects is vital for designing inhibitors that are both specific to their target and effective in their inhibitory action. The interaction between the inhibitors and the LOC100039248 protein is a key area of study, as it determines the success of the inhibition process. The inhibitors must bind to the protein in a way that disrupts its ability to interact with other cellular components or carry out its normal functions. This typically involves the formation of a complex between the inhibitor and specific regions on the protein, requiring a highly precise match in molecular structures. In addition to their binding characteristics, the design of LOC100039248 inhibitors also takes into account the compound's stability, solubility, and its ability to effectively reach and interact with the target within biological systems. Researchers strive to optimize the pharmacokinetic properties of these inhibitors, ensuring that they have suitable hydrophobic and hydrophilic characteristics and an appropriate molecular size and shape for efficient interaction. The pursuit of LOC100039248 inhibitors showcases the advanced level of current research in molecular targeting and the intricate processes involved in designing inhibitors for specific, yet less characterized proteins.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rifampicin | 13292-46-1 | sc-200910 sc-200910A sc-200910B sc-200910C | 1 g 5 g 100 g 250 g | $97.00 $328.00 $676.00 $1467.00 | 6 | |
Rifampicin binds to bacterial RNA polymerase, inhibiting transcription initiation. In eukaryotes, it can also inhibit DNA-dependent RNA polymerase. | ||||||
Puromycin | 53-79-2 | sc-205821 sc-205821A | 10 mg 25 mg | $166.00 $322.00 | 436 | |
Puromycin causes premature chain termination during translation by acting as an analog of the 3'-end of aminoacyl-tRNA. | ||||||
Streptonigrin | 3930-19-6 | sc-500892 sc-500892A | 1 mg 5 mg | $104.00 $364.00 | 1 | |
Streptolydigin binds to RNA polymerase and inhibits the elongation phase of RNA synthesis, affecting gene expression. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin interferes with peptide elongation by inhibiting peptidyl transferase activity on the ribosome, affecting protein synthesis. | ||||||
Cordycepin | 73-03-0 | sc-203902 | 10 mg | $101.00 | 5 | |
Cordycepin is an adenosine analog that can terminate RNA chain elongation due to the absence of a hydroxyl group at the 3' position. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation and can also interfere with lipid-linked oligosaccharide synthesis, affecting protein expression. | ||||||
Emetine | 483-18-1 | sc-470668 sc-470668A sc-470668B sc-470668C | 1 mg 10 mg 50 mg 100 mg | $440.00 $900.00 $1400.00 $2502.00 | ||
Emetine inhibits the elongation step of protein synthesis by binding to the eukaryotic ribosome, affecting gene expression. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Camptothecin inhibits DNA topoisomerase I, which can lead to DNA damage and potentially alter gene expression patterns. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $66.00 $101.00 $143.00 | 85 | |
Mitomycin C forms cross-links in DNA, which could prevent transcription and decrease gene expression. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib inhibits the 26S proteasome, leading to an accumulation of proteins that can alter various cellular pathways and gene expression. | ||||||